US20190167605A1 – June 6, 2019 – TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL

Please complete the required fields.




Inventors :

Marcel Bonn-Miller; Nancy Tich; Donna Gutterman; John Messenheimer; Terri Sebree

Owner :

ZYNERBA PHARMACEUTICALS, INC.

Application Number :

US16249732

Document Number :

US20190167605A1

Priority Date :

January 16, 2019

Filing Date :

January 16, 2019

Date of Grant/ Publication :

June 6, 2019

Class :

; A61K31 / 05; A61K9 / 06; A61K36 / 185; A61P25 / 00; A61K9 / 00

Abstract

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

Claim(s)

31 . A method of treating a human suffering from Fragile X Syndrome comprising: transdermally administering 250 mg or 500 mg of cannabidiol total daily to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login